BACKGROUND: Increases in multidrug-resistance among gram-negative organisms have necessitated the use of polymyxins. To date, the incidence of acute kidney injury (AKI) associated with polymyxin B has not been evaluated using RIFLE criteria. METHODS: Adult patients who received polymyxin B were retrospectively evaluated to determine the incidence of AKI during polymyxin B therapy using RIFLE criteria. Predictors of AKI were identified by comparing characteristics of patients with and without AKI. RESULTS: A total of 73 patients were included. The incidence of AKI was 60%. Ten (14%) patients discontinued therapy due to nephrotoxicity. Median duration of polymyxin B was 11 days with a median cumulative dose of 18 mg/kg. Concomitant nephrotoxins were received in 69 (95%). Patients with AKI had a higher median cumulative dose (1578 mg vs. 800 mg; p = 0.02), a higher body mass index (BMI) (27.2 vs. 24.5 kg/m(2); p = 0.03), and were more likely to receive vancomycin (82% vs. 55%; p = 0.03) compared to those without AKI. After controlling for polymyxin B duration, independent predictors of AKI were higher BMI and concomitant vancomycin. CONCLUSIONS: The incidence of AKI during polymyxin B therapy was 60%. Further studies are needed to define dosing parameters that maximize efficacy and minimize nephrotoxicity.
BACKGROUND: Increases in multidrug-resistance among gram-negative organisms have necessitated the use of polymyxins. To date, the incidence of acute kidney injury (AKI) associated with polymyxin B has not been evaluated using RIFLE criteria. METHODS: Adult patients who received polymyxin B were retrospectively evaluated to determine the incidence of AKI during polymyxin B therapy using RIFLE criteria. Predictors of AKI were identified by comparing characteristics of patients with and without AKI. RESULTS: A total of 73 patients were included. The incidence of AKI was 60%. Ten (14%) patients discontinued therapy due to nephrotoxicity. Median duration of polymyxin B was 11 days with a median cumulative dose of 18 mg/kg. Concomitant nephrotoxins were received in 69 (95%). Patients with AKI had a higher median cumulative dose (1578 mg vs. 800 mg; p = 0.02), a higher body mass index (BMI) (27.2 vs. 24.5 kg/m(2); p = 0.03), and were more likely to receive vancomycin (82% vs. 55%; p = 0.03) compared to those without AKI. After controlling for polymyxin B duration, independent predictors of AKI were higher BMI and concomitant vancomycin. CONCLUSIONS: The incidence of AKI during polymyxin B therapy was 60%. Further studies are needed to define dosing parameters that maximize efficacy and minimize nephrotoxicity.
Authors: Bo Yun; Mohammad A K Azad; Cameron J Nowell; Roger L Nation; Philip E Thompson; Kade D Roberts; Tony Velkov; Jian Li Journal: Antimicrob Agents Chemother Date: 2015-09-21 Impact factor: 5.191
Authors: Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin Journal: Antimicrob Agents Chemother Date: 2015-08-31 Impact factor: 5.191
Authors: Cristina Miglis; Nathaniel J Rhodes; Sean N Avedissian; Christine J Kubin; Michael T Yin; Brian C Nelson; Manjunath P Pai; Marc H Scheetz Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Rajnikant Sharma; Saloni Patel; Cely Abboud; John Diep; Neang S Ly; Jason M Pogue; Keith S Kaye; Jian Li; Gauri G Rao Journal: Int J Antimicrob Agents Date: 2016-12-23 Impact factor: 5.283
Authors: Elijah J Weber; Kevin A Lidberg; Lu Wang; Theo K Bammler; James W MacDonald; Mavis J Li; Michelle Redhair; William M Atkins; Cecilia Tran; Kelly M Hines; Josi Herron; Libin Xu; Maria Beatriz Monteiro; Susanne Ramm; Vishal Vaidya; Martti Vaara; Timo Vaara; Jonathan Himmelfarb; Edward J Kelly Journal: JCI Insight Date: 2018-12-20
Authors: Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li Journal: ACS Infect Dis Date: 2015-09-04 Impact factor: 5.084
Authors: Tony Velkov; Bo Yun; Elena K Schneider; Mohammad A K Azad; Olan Dolezal; Faye C Morris; Roger L Nation; Jiping Wang; Ke Chen; Heidi H Yu; Lv Wang; Philip E Thompson; Kade D Roberts; Jian Li Journal: ACS Infect Dis Date: 2016-03-29 Impact factor: 5.084